Given that IgM+ memory B cells are the main subpopulation in the secondary responses with high expressions of HLA-DR (Figure S6C), they might be engaged in promoting anti-tumor immunity through remodeling the capacity of antigen presentation upon nivolumab immunotherapy. This evidence concerns the gene CD40LG and neoplasm.